Showing results (61-70 of 163) with videos related to
Sort By:
Pageof 17
Journal of Cancer Research and Clinical Oncology|December 4, 2018
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysisBiagio Ricciuti, Carlo Genova, Andrea De Giglio, et al.Journal of Chemotherapy (Florence, Italy)|December 20, 2022
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two casesGiulio Metro, Sara Baglivo, Niccolò Metelli, et al.The Breast Journal|November 6, 2009
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancerGiulio Metro, Diana Giannarelli, Donatello Gemma, et al.Journal of Neuro-Oncology|June 22, 2016
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case seriesGiulio Metro, Gianluigi Lunardi, Chiara Bennati, et al.Ecancermedicalscience|August 19, 2015
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case reportGiulio Metro, Emanuele Valtorta, Annamaria Siggillino, et al.Drugs in Context|December 1, 2022
How to manage <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancerBiagio Ricciuti, Alessia Mira, Elisa Andrini, et al.Expert Opinion on Pharmacotherapy|October 7, 2015
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancerGiulio Metro, Rita Chiari, Biagio Ricciuti, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
OsimertinibUmberto Malapelle, Biagio Ricciuti, Sara Baglivo, et al.Journal of Neuro-Oncology|March 31, 2010
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II studyAlessandra Fabi, Giulio Metro, Antonello Vidiri, et al.Translational Lung Cancer Research|September 21, 2020
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumabGiuseppe Luigi Banna, Diego Signorelli, Giulio Metro, et al.Pageof 17